King Pharmaceuticals KG Net unrealized gains on fixed maturity investments
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:InvestmentsNetUnrealizedGainLoss.
The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about King Pharmaceuticals's net unrealized gains on fixed maturity investments.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is King Pharmaceuticals's net unrealized gains on fixed maturity investments?
- King Pharmaceuticals (KG) reported net unrealized gains on fixed maturity investments of $78K in Q1 2026.